Clinical utility of circulating tumor cells for predicting major histopathological response after neoadjuvant chemoradiotherapy in patients with esophageal cancer

HIGHLIGHTS

SUMMARY

Neoadjuvant chemoradiotherapy (nCRT) followed by surgery is a standard first-line therapeutic strategy for patients with locally advanced esophageal cancer (EC). While data are promising in several solid cancers - including breast, pancreatic, colorectal, and esophageal malignancies, the questions as to whether the CTCs count may be clinically useful in the identification of EC patients with MaHR after nCRT remains unanswered. No cCR cCR CTC count ≥5 per mL of blood CTC count and amp;lt;5 per mL of blood Non-cCR or CTC count ≥5 per mL of blood cCR and CTC count . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.